Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Total Liabilities (2020 - 2025)

Caribou Biosciences has reported Total Liabilities over the past 6 years, most recently at $53.2 million for Q4 2025.

  • Quarterly Total Liabilities fell 11.88% to $53.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $53.2 million through Dec 2025, down 11.88% year-over-year, with the annual reading at $53.2 million for FY2025, 11.88% down from the prior year.
  • Total Liabilities was $53.2 million for Q4 2025 at Caribou Biosciences, roughly flat from $53.1 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $80.2 million in Q2 2023 and troughed at $35.7 million in Q1 2021.
  • The 5-year median for Total Liabilities is $61.4 million (2024), against an average of $61.9 million.
  • Year-over-year, Total Liabilities skyrocketed 1599.48% in 2021 and then decreased 22.09% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $54.5 million in 2021, then surged by 33.67% to $72.9 million in 2022, then fell by 12.46% to $63.8 million in 2023, then fell by 5.4% to $60.4 million in 2024, then fell by 11.88% to $53.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Total Liabilities are $53.2 million (Q4 2025), $53.1 million (Q3 2025), and $54.8 million (Q2 2025).